Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (95)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Myeloma (293)
  5. Survivorship Research (212)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (9)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (95)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (105)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low target antigen expression mediates resistance to BCMA CAR T cell therapy
    Meeting Abstract

    Perica, K.; Nataraj, S.; Sjojstrand, M. L.; Nagel, K.; Pavkovic, E.; Payson, E.; Cuenca, A.; Patel, A.; Chung, D.; Mailankody, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Current use of CAR T cells to treat multiple myeloma
    Review

    Firestone, R. S.; Mailankody, S.
    Hematology-American Society of Hematology Education Program (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save